


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted: (use as many sheets as necessary)				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	30	Attorney Docket Number	034536-0188

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
RJ	B1	Re. 35,096	E	Taniguchi et al.	11-21-1995	
RJ	B2	Re. 36,256	E	Spada et al.	07-20-1999	
RJ	B3	2,622,980		Copeland	12-23-1952	
RJ	B4	2,872,372		Hull	02-03-1959	
RJ	B5	2,968,557		Burgandt et al.	01-17-1961	
RJ	B6	3,140,180		Fritz	07-07-1964	
RJ	B7	3,308,134		Plostneiks	03-07-1967	
RJ	B8	3,551,571		Pachter et al.	12-29-1970	
RJ	B9	3,564,016		Schoen et al.	02-16-1971	
RJ	B10	3,715,364		Hoff	02-06-1973	
RJ	B11	3,880,871		Haugwitz et al.	04-29-1975	
RJ	B12	3,922,163		Church et al.	11-25-1975	
RJ	B13	4,002,643		Carson	01-11-1977	
RJ	B14	4,002,749		Rovnyak	01-11-1977	
RJ	B15	4,053,613		Rovnyak et al.	10-11-1977	
RJ	B16	4,070,366		Gregorovich et al.	01-24-1978	
RJ	B17	4,259,345		Cross et al.	03-31-1981	
RJ	B18	4,343,923		Lenox et al.	08-10-1982	

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See Attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted:				Prior Appl. Filing Date	February 15, 2002
(use as many sheets as necessary)				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	30	Attorney Docket Number	034536-0188

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PL	B19	4,376,110		David et al.	03-08-1983	
PL	B20	4,436,892		Zondler et al.	03-13-1984	
PL	B21	4,489,089		Wright, Jr. et al.	12-18-1984	
PL	B22	4,493,842		Furazawa et al.	01-15-1985	
PL	B23	4,560,700		Schnettler et al.	12-24-1985	
PL	B24	4,628,105		Schmid et al.	12-09-1986	
PL	B25	4,642,309		Michel et al.	02-10-1987	
PL	B26	4,678,798		Rentzea et al.	07-07-1987	
PL	B27	4,826,847		Michel et al.	05-02-1989	
PL	B28	4,853,403		Shiraishi et al.	08-01-1989	
PL	B29	4,853,404		Takamura et al.	08-01-1989	
PL	B30	4,868,304		Larock	09-19-1989	
PL	B31	4,924,000		Rentzea et al.	05-08-1990	
PL	B32	4,966,849		Vallee et al.	10-30-1990	
PL	B33	4,971,996		Shiraishi et al.	11-20-1990	
PL	B34	4,987,146		Rohde et al.	01-22-1991	
LG	B35	5,043,348		Zoller et al.	08-27-1991	
PL	B36	5,043,454		Wriede et al.	08-27-1991	

Examiner Signature		Date Considered	12/12/05
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted:				Prior Appl. Filing Date	February 15, 2002
(use as many sheets as necessary)				First Named Inventor	Huiping GUAN et al.
Sheet	3	of	30	Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
RH	B37	5,047,554		Ehrgott et al.	09-10-1991	
RH	B38	5,051,417		Nadler et al.	09-24-1991	
LH	B39	5,057,538		Shiraishi et al.	10-15-1991	
PA	B40	5,082,856	A	Taniguchi et al.	01-21-1992	
RG	B41	5,089,516	A	Shiraishi et al.	02-18-1992	
RH	B42	5,124,347	A	Connor et al.	06-23-1992	
RH	B43	5,145,983	A	West	09-08-1992	
RH	B44	5,153,217	A	Taniguchi et al.	10-06-1992	
RH	B45	5,196,446	A	Levitzki et al.	03-23-1993	
RH	B46	5,202,341	A	Shiraishi et al.	04-13-1993	
RH	B47	5,206,261	A	Kawaguchi et al.	04-27-1993	
RH	B48	5,217,999	A	Levitzki et al.	06-08-1993	
RH	B49	5,258,357	A	Muenster et al.	11-02-1993	
RH	B50	5,278,184	A	Artico et al.	01-11-1994	
AK	B51	5,290,947	A	Zoller et al.	03-01-1994	
AK	B52	5,302,606	A	Spada et al.	04-12-1994	
RH	B53	5,322,950	A	Sircar et al.	06-21-1994	
RH	B54	5,330,992	A	Eissenstat et al.	07-19-1994	

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	4	of	30	Prior Application Number	10/076,140
				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
RL	B55	5,332,736	A	Carmosin et al.	07-26-1994	
RL	B56	5,374,652	A	Buzzetti et al.	12-20-1994	
RL	B57	5,382,593	A	Le Baut et al.	01-17-1995	
RL	B58	5,389,661	A	Sircar et al.	02-14-1995	
RL	B59	5,397,787	A	Buzzetti et al.	03-14-1995	
RL	B60	5,409,930	A	Spada et al.	04-25-1995	
RL	B61	5,409,949	A	Buzzetti et al.	04-25-1995	
RL	B62	5,463,052	A	Haga et al.	10-31-1995	
RL	B63	5,565,324	A	Still et al.	10-15-1996	
RL	B64	5,610,173	A	Schwartz et al.	03-11-1997	
RL	B65	5,723,665	A	Kato et al.	03-03-1998	
RL	B66	5,786,488	A	Tang et al.	07-28-1998	
RL	B67	5,792,783	A	Tang et al.	08-11-1998	
RL	B68	5,834,504	A	Tang et al.	11-10-1998	
RL	B69	5,849,710	A	Battistini et al.	12-15-1998	
RL	B70	5,880,141	A	Tang et al.	03-09-1999	
RL	B71	5,883,113	A	Tang et al.	03-16-1999	
RL	B72	5,883,116	A	Tang et al.	03-16-1999	

Examiner Signature	<i>Robert Lander</i>	Date Considered	12/2/05
--------------------	----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	5	of	30	Prior Application Number	10/076,140
				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
<i>PL</i>	B73	5,886,020	A	Tang et al.	03-23-1999	
<i>PL</i>	B74	6,130,239	A	Chen et al.	10-10-2000	
<i>PL</i>	B75	6,133,305	A	Tang et al.	10-17-2000	
<i>PL</i>	B76	6,284,894	B1	Phillion et al.	09-04-2001	
<i>PL</i>	B77	6,310,217	B1	Lehr	10-30-2001	
<i>PL</i>	B78	6,395,736		Parks et al.	05-28-2002	
<i>PL</i>	B79	6,451,838		Moon et al.	09-17-2002	
<i>PL</i>	B80	6,462,072		Hamilton et al.	10-08-2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>5</sup> (if known)				
<i>PL</i>	B81	WO	88/07035	A1	KANEKA FUCHI KAGAKU KOGYO KABUSHIKI KAISHA	09-22-1988		
<i>PL</i>	B82	WO	91/13055	A2	FARMITALIA CARLO ERBA SRL	09-05-1991		
<i>PL</i>	B83	WO	91/15495	A1	PFIZER INC.	10-17-1991		
<i>PL</i>	B84	WO	92/03736	A1	SEIKAGAKU KOGYO KABUSHIKI KAISHA	03-05-1992		
<i>PL</i>	B85	WO	92/07830	A2	PFIZER INC.	05-14-1992		
<i>PL</i>	B86	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL	11-26-1992		
<i>PL</i>	B87	WO	92/21660	A1	PFIZER INC.	12-10-1992		

Examiner Signature	<i>Lehr</i>	Date Considered	<i>12/15</i>
--------------------	-------------	-----------------	--------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	6	of	30	Prior Application Number	10/076,140
				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
le	B88	WO	93/01182	A1	FARMITALIA CARLO ERA SRL	01-21-1993		
AS	B89	WO	93/23040	A1	MERCK & CO., INC.	11-25-1993		
AS	B90	WO	94/03427	A1	WARNER-LAMBERT COMPANY	02-17-1994		
AS	B91	WO	94/10202	A1	GENENTECH, INC.	05-11-1994		
AS	B92	WO	94/14808	A1	FARMITALIA CARLO ERBA SRL	07-07-1994		
AS	B93	WO	95/01349	A1	FARMITALIA CARLO ERBA SRL	01-12-1995		
AS	B94	WO	95/14667	A1	PFIZER INC.	06-01-1995		
AS	B95	WO	95/17181	A1	PHARMACIA S.P.A.	06-29-1995		
AS	B96	WO	95/24190	A2	SUGEN, INC.	09-14-1995		
AS	B97	WO	96/00226	A1	PHARMACIA S.P.A.	01-04-1996		
AS	B98	WO	96/16964	A1	PHARMACIA S.P.A.	06-06-1996		
AS	B99	WO	96/22976	A1	PHARMACIA S.P.A.	08-01-1996		
AS	B100	WO	96/32380	A1	PHARMACIA S.P.A.	10-17-1996		
AS	B101	WO	96/40116	A1	SUGEN, INC.	12-19-1996		
AS	B102	WO	97/25986	A1	TAIHO PHARMACEUTICAL CO., LTD.	07-24-1997		
AS	B103	WO	97/34920	A1	SUGEN, INC.	09-25-1997		
AS	B104	WO	97/36867	A1	PFIZER, INC.	10-09-1997		
AS	B105	WO	98/07695	A1	SUGEN, INC.	02-26-1998		

Examiner Signature		Date Considered	12/12/05
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)					<b>Complete If Known</b>	
Sheet	7	of	30		Prior Application Number	10/076,140
					Prior Appl. Filing Date	February 15, 2002
					First Named Inventor	Huiping GUAN et al.
					Group Art Unit	Unassigned
					Examiner Name	Unassigned
					Attorney Docket Number	034536-0188

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>2</sup>	Number	Kind Code <sup>5</sup> (if known)				
RJ	B106	WO	98/07835	A2	SUGEN, INC.	02-26-1998		
RJ	B107	WO	98/24432	A2	SUGEN, INC.	06-11-1998		
RJ	B108	WO	98/38984	A2	SUGEN, INC.	09-11-1998		
RJ	B109	WO	98/45708	A1	SUGEN, INC.	10-15-1998		
RJ	B110	WO	98/50356	A1	SUGEN, INC.	11-12-1998		
RJ	B111	WO	98/56376	A1	SUGEN, INC.	12-17-1998		
RJ	B112	WO	99/10325	A1	GLAXO GROUP LIMITED	03-04-1999		
RJ	B113	WO	99/19325	A1	SYNTHELABO	04-22-1999		
RJ	B114	WO	99/48868	A2	SUGEN, INC.	09-30-1999		
RJ	B115	WO	99/52869	A1	BOEHRINGER INGELHEIM PHARMA KG	10-21-1999		
RJ	B116	WO	99/65869	A1	BAYER AKTIENGESELLSCHAFT	12-23-1999		
RJ	B117	WO	99/61422	A1	SUGEN, INC.	12-02-1999		
RJ	B118	WO	00/35920	A2	F. HOFFMANN-LA ROCHE AG	06-22-2000		
RJ	B119	WO	00/38519	A1	SUGEN, INC.	07-06-2000		
RJ	B120	WO	00/08202	A2	SUGEN, INC.	02-17-2000		
RJ	B121	WO	00/56709	A1	SUGEN, INC.	09-28-2000		
RJ	B122	WO	01/60814	A2	SUGEN, INC.	08-23-2001		
RJ	B123	WO	01/90068	A2	SUGEN, INC. et al.	11-29-2001		
RJ	B124	DE	878,539		Von FREYBERG, et al.	06-05-1953		X

Examiner Signature		Date Considered	12/12/05
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)				<b>Complete If Known</b>	
Sheet	8	of	30	Prior Application Number	10/076,140
				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
RJ	B125	DE	2,159,360	A	BAYER AG	06-14-1973		X
M	B126	DE	2,159,361	A	BAYER AG	06-14-1973		X
PA	B127	DE	2,159,362		BAYER AG	06-14-1973		
M	B128	DE	2,159,363	A	BAYER AG	06-14-1973		X
AS	B129	DE	2,321,656	A	COLGATE-PALMOLIVE CO.	11-15-1973		X
AS	B130	DE	3,426,419	A	BOEHRINGER MANNHEIM GMBH	01-23-1986		X
PA	B131	EP	0 252 713	B1	PFIZER INC.	01-13-1988		
PK	B132	EP	0 304 493	B1	KANEKA FUCHI KAGAKU KOGTO KABUSHIKI KAISHA	03-01-1989		
AS	B133	EP	0 351 213	A2	LES LABORATOIRES BEECHAM S.A.	01-17-1990		
RJ	B134	EP	0 525 472	A2	FARMITALIA CARLO ERBA SRL	02-03-1993		
RJ	B135	EP	0 566 226	B1	ZENECA LIMITED	10-20-1993		
RJ	B136	EP	0 580 502	B1	ADIR ET COMPAGNIE	01-26-1994		X
M	B137	EP	0 626 377	B1	SHIONOGI & CO., LTD.	11-30-1994		
AS	B138	EP	0 632 102	A1	BAYER AG	01-04-1995		X
AS	B139	EP	0 662 473	A1	PHARMACIA S.P.A.	07-12-1995		
AS	B140	EP	0 788 890	A1	AGFA-GEVAERT	08-13-1997		
AS	B141	EP	0 810 217	A1	JAPAN ENERGY CORPORATION	12-03-1997		
PL	B142	EP	0 769 947	B1	TANG, Peng Cho et al.	05-02-1997		

Examiner Signature	<i>Karen Adler</i>	Date Considered	<i>12/12/05</i>
--------------------	--------------------	-----------------	-----------------

\*EXAMINER: Initial if reference considered (whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)					<b>Complete If Known</b>	
Sheet	9	of	30		Prior Application Number	10/076,140
					Prior Appl. Filing Date	February 15, 2002
					First Named Inventor	Huiping GUAN et al.
					Group Art Unit	Unassigned
					Examiner Name	Unassigned
					Attorney Docket Number	034536-0188

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
RJ	B143	EP	0 934 931	A2	SUGEN, INC.	08-11-1999		
RJ	B144	EP	1 082 305	A1	SUGEN, INC.	03-14-2001		
RJ	B145	FR	1.398.224		IMPERIAL CHEMICAL INDUSTRIES LIMITED	05-07-1965		X
RJ	B146	FR	1.599.772		INSTITUT PASTEUR	08-28-1970		X
RJ	B147	FR	2.689.397	A1	ADIR ET COMPAGNIE	10-08-1993		X
RJ	B148	GB	809,691		Roy HULL	03-04-1959		
RJ	B149	GB	835,473		Norman SENIOR	05-18-1960		
RJ	B150	JP	62-29570	A	KANEKA CORP	02-07-1987		X
RJ	B151	JP	62-39564	A	KANEKA CORP	02-20-1987		X
RJ	B152	JP	63-141955	A	KANEKA CORP	06-14-1988		X
RJ	B153	JP	5-58894	A	KANEKA CORP	03-09-1993		X
RJ	B154	CA	2,012,634	A1	UNIVERSITY OF BRITISH COLUMBIA	09-20-1991		
RJ	B155	AU	286870		IMPERIAL CHEMICAL INDUSTRIES OF AUSTRALIA AND NEW ZEALAND LIMITED	05-11-1967		

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted: (use as many sheets as necessary)				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	10	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>RJ</i>	B156	ABRAMOVITCH and HEY, "Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles," <u>J. Chem. Soc.</u> , 1697-1703 (1954), Strand, London			
<i>RJ</i>	B157	ABRAMOVITCH et al., "A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement," <u>Chemistry and Industry</u> 44:1871 (1967) 8 Laporte Industries Limited, Lancashire			
	B158	<del>Beilstein Reg. No. 236050, Beilstein Reference No. 4-24-00-06355</del>			
<i>RJ</i>	B159	AKBASAK and SUNAR-AKBASAK, "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992) 8 Elsevier Science Publishers			
<i>RJ</i>	B160	ANDREANI et al., "Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene)1,3-Dihydroindol-2-Ones," <u>Anticancer Research</u> 16:3585-3588 (1996) 8 Elsevier, Paris			
<i>RJ</i>	B161	ANDREANI et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25:187-190 (1990)			
<i>RJ</i>	B162	ANDREANI et al., "Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups," <u>Eur. J. Med. Chem.</u> 28:653-657 (1993) 8 Elsevier, Paris			
<i>RJ</i>	B163	ANDREANI et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Chemical Abstracts</u> , Vol. 113, abstract no. 78106 (1990)			
<i>RJ</i>	B164	ANDREANI et al., "Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones," <u>Eur. J. Med. Chem.</u> 27:167-170 (1992) 8 Elsevier, Paris			
<i>RJ</i>	B165	ANDREANI et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924 (1997) 8 Elsevier, Paris			
<i>RJ</i>	B166	ANDREANI et al., "Synthesis of lactams with potential cardiotonic activity," <u>Eur. J. Med. Chem.</u> 28:825-829 (1993)			
<i>RJ</i>	B167	ANDREANI et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," <u>Arzneimittel-Forschung Drug Research</u> 48:727-729 (1998) 8			

Examiner Signature	<i>Robert Anderson</i>	Date Considered	<i>12/2/05</i>
--------------------	------------------------	-----------------	----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

\* the reference has no date *RJ*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted: (use as many sheets as necessary)				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	11	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RH	B168	ARTEAGA et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989) copyright The American Society for Clinical Investigation, Inc.			
RH	B169	ARVIDSSON et al., "Tyr-716 in the Platelet-Derived Growth Factor β-Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726 (1994) 8 The American Society for Microbiology			
RH	B170	AUTREY and TAHK, "The Synthesis and Stereochemistry of Some Isatylideneacetic Acid Derivatives," <u>Tetrahedron</u> 23:901-917 (1967) 8 Pergamon Press			
RH	B171	BAHNER and BROTHERTON, "6-Dimethylaminochrysene and Other Analogs of 4-(4-Dimethylamino)stilbene," <u>J. Med. Chem.</u> 12:722-723 (1969)			
RH	B172	BAHNER et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," <u>J. Med. Chem.</u> 12:721-722 (1969)			
RH	B173	BAMFIELD et al., "Diels-Alder Reactions of Oxindolylideneacetone," <u>J. Chem. Soc. (C)</u> 1028-1030 (1966) 8			
RH	B174	BARBIER, et al., "Synthesis of Isobrassilexin, A Biologically Active Isomer of Brassilexin, a Cruciferae Phytoalexin," <u>Synthetic Communications</u> 23(22):3109-3117 (1993) 8 Marcel Dekker, Inc.			
RH	B175	BASERGA, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-930 (1994) 8 Cell Press			
RH	B176	BASERGA, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (1995)			

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted:				Prior Appl. Filing Date	February 15, 2002
(use as many sheets as necessary)				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	12	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RJ	B177	Beilstein Reg. No. 233511 (1997)			
RJ	B178	Beilstein Reg. No. 235647 (1997)			
RJ	B179	Beilstein Reg. No. 252929 (1998)			
RJ	B180	BENZIES, et al., "2-Formyl-3-Methoxymethylindole, 3-Ethoxymethyl-2-Formylindoline and 2-Formyl-3-Methylindole," <u>Synthetic Communications</u> : 16(14), 1799-1807 (1986) 8 Marcel Dekker, Inc.			
RJ	B181	BLAKE and JAQUES, "Anisotropic Effects in $\alpha$ -Substituted Methoxystilbenes," <u>J. Chem. Soc. Perkin II</u> : 1660-1663 (1973) 8 Pergamon, Oxford			
RJ	B182	BOLEN et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)			
RJ	B183	BOLEN, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993) copyright MacMillan Press Ltd.			
RJ	B184	BONNER et al., "Structure and Biological Activity of Human Homologs of the raf/mil Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1985) 8 The American Society for Microbiology			
RJ	B185	BORSCHE et al., "Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII.," <u>Liebigs Ann. Chem.</u> 550:160-174 (1941)			

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted:				Prior Appl. Filing Date	February 15, 2002
(use as many sheets as necessary)				First Named Inventor	Huiping GUAN et al.
Sheet	13	of	30	Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
RF	B186	BUZZETTI et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>Il Farmaco</u> 48:615-636 (1993)				
RF	B187	CANCE et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993) 8 Wiley-Liss, Inc.				
RF	B188	CANOIRA and RODRIGUEZ, "Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex," <u>J. Heterocyclic Chem.</u> 22:1511-1518 (1985)				
RF	B189	CARPENEDO et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," <u>Analytical Biochemistry</u> 244:74-79 (1997) 8 Academic Press, Inc.				
RA	B190	CHAO, "Growth Factor Signaling: Where Is the Specificity?" <u>Cell</u> 68:995-997 (1992) copyright Cell Press				
RF	B191	CHATDEN et al., "Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted <i>trans</i> -3-Benzylideneindol-2(3H)-ones," <u>J. Chem. Soc. Perkin II</u> : 469-473 (1973)				
	B192	CHATTERJEE et al., "Acylation of Indoles by Duff Reaction and Vilsmeier-Haack Formylation and Conformation of <i>N</i> -Formylindoles," <u>J. Org. Chem.</u> , 38:4002-4004 8The American Chemical Society				
RF	B193	CHEN et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on $\gamma$ -Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron," <u>Chinese Journal of Physiology</u> 40:149-156 (1997)				
RF	B194	CLAESSON-WELSH, "Signal Transduction by the PDGF Receptors," <u>Progress in Growth Factor Research</u> 5:37-54 (1994) 8 Elsevier Science Ltd.				

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

\* no date provided RF

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted: (use as many sheets as necessary)				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet 14		of 30	Attorney Docket Number		034536-0188

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RF	B195	CODA et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>J. Chem. Soc. Perkin Trans. II</u> : 615-619 (1984)			
Rf	B196	CODA et al., "3-(4-methylbenzilidene)-1,3-dihydroindol-2-one," <u>Journal of the Chemical Society, Perkin Transactions 2</u> 4:615-620 (1984) DATABASE CROSSFIRE, Beilstein Reference No. 6-21			
RF	B197	COPPOLA et al., "A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14:4588-4595 (1994) 8 The American Society for Microbiology			
RF	B198	DAISLEY and WALKER, "Thin-layer chromatographic separation of some substituted 3-benzylidine-indol-2(3H)-ones," <u>J. Chromatography</u> 100:240-242 (1974) 8 Elsevier Scientific Publishing Company			
RF	B199	DAMIANI et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48:1155-1161 (1994) copyright Elsevier Science Ltd.			
RJ	B200	DATI et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells," <u>Oncogene</u> 5:1001-1006 (1990)			
Rf	B201	DAVIS et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16:1043-1045 (1973) 8American Chemical Society			
RF	B202	DE VRIES et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992)			
RF	B203	DECKER and LOHMANN-MATTHES, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 15:61-69 (1988) copyright Elsevier			

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted: (use as many sheets as necessary)				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Hulping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	15	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
PF	B204	DECODTS et al., "Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams," <u>Eur. J. Med. Chem.</u> 18: 107-111 (1983)			
PF	B205	DESIMONI et al., "Catalysis with Inorganic Cations. V <sup>1</sup> Intramolecular Hetero Diels-Alder versus Ene Reactions: Effect of Magnesium perchlorate on Chemoselectivity," <u>Tetrahedron</u> 52(36) 12009-12018 (1996) 8 Pergamon			
PF	B206	DICKSON et al., "13. Tyrosine kinase receptor - nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992) 8 Kluwer Academic Publishers			
PF	B207	ELLIOTT and RIVERS, "Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride," <u>J. Med. Chem.</u> 29:2438-2440 (1964)			
PF	B208	ELLIOTT et al., "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," <u>Journal of Organic Chemistry</u> 29:2438-2440 (1964) DATABASE CROSSFIRE, Beilstein Reference No. 5-24			
PF	B209	FANTL et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992) 8 Cell Press			
PF	B210	FENDLY et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product," <u>Cancer Research</u> 50:1550-1558 (1990); @ American Association for Cancer Research			
PF	B211	FERRARA and HENZEL, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989) 8 Academic Press, Inc.			
PF	B212	FINGL and WOODBURY, "Chapter 1 - General Principles," in <u>The Pharmacological Basis of Therapeutics</u> 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York , pp. 1-46 (1975) 8 MacMillan Publishing Co. Inc.			

Examiner Signature		Date Considered	12/12/05
--------------------	---	-----------------	----------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted:				Prior Appl. Filing Date	February 15, 2002
(use as many sheets as necessary)				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	16	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>AS</i>	B213	FLOEGE et al., "Factors involved in the regulation of mesangial cell proliferation <i>in vitro</i> and <i>in vivo</i> ," <u>Kidney International</u> 43:S47-S54 (1993) 8 International Society of Nephrology			
<i>AS</i>	B214	FLOEGE et al., "Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis," <u>Kidney International</u> 43:369-380 (1993) 8 International Society of Nephrology			
<i>AS</i>	B215	FOLKMAN and SHING, "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992) 8 The American Society for Biochemistry and Molecular Biology			
<i>AS</i>	B216	FOLKMAN, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)			
<i>AS</i>	B217	FOLKMAN, "Tumor Angiogenesis: Therapeutic Implications," <u>New England J. Medicine</u> 285:1182-1186 (1971)			
<i>AS</i>	B218	FOLKMAN, "What is the Evidence that Tumors are Angiogenesis Dependent?" <u>Journal of the National Cancer Institute</u> 82:4-6 (1990)			
<i>AS</i>	B219	FOLKMAN, "Angiogenesis in Psoriasis: Therapeutic Implications," <u>J. Invest. Dermatol.</u> 59:40-43 (1973) copyright The Williams & Wilkins Co.			
<i>AS</i>	B220	GAZIT et al., "Tyrphostins. 2. Heterocyclic and $\alpha$ -Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <u>J. Med. Chem.</u> 34:1896-1907 (1991) copyright Am. Clem. Soc.			
<i>AS</i>	B221	GENNARO (editor), <u>Remington's Pharmaceutical Sciences</u> (1990) (TABLE OF CONTENTS ONLY)			

Examiner Signature	<i>Leah A. Sander</i>	Date Considered	<i>12/2/05</i>
--------------------	-----------------------	-----------------	----------------

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted: (use as many sheets as necessary)				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	17	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
RJ	B222	GOLDRING and GOLDRING, "Cytokines and Cell Growth Control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)				
RJ	B223	GOTTARDIS et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumorstatic Action of Tamoxifen," <u>J. Steroid Biochem.</u> 30:311-314 (1988) 8 Pergamon Press				
RJ	B224	GRAZIANI et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," <u>The Journal of Biological Chemistry</u> 268:9165-9168 (1993) 8American Society for Biochemistry and Molecular Biology				
RJ	B225	HAYLER et al., Development of Large-Scale Syntheses of Ropinirole in the Pursuit if a Manufacturing Process," <u>Organic Process Research &amp; Development</u> 2(1) 3-9 (1998) 8The American Chemical Society and Royal Society of Chemistry				
RJ	B226	HEWGILL and STEWART, "Phenanthrene-4,5-quinones: a Synthesis of Morphenol," <u>J. Chem. Soc. Perkin Trans. I</u> :1305-1311 (1988)				
RJ	B227	HIRAO et al., "Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Syntheses of 1,3-Dihydroindol-2-ones," <u>Tetrahedron Letters</u> 36(35) 1995 8Pergamon				
RJ	B228	HODGES et al., "Chemical and biological properties of some oxindolidyl-3-methines," <u>Canadian J. Chemistry</u> 46:2189-2194 (1968)				
RJ	B229	HONEGGER et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 51:199-209 (1987) 8 Cell Press				
RJ	B230	HOUCK et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>J. Biol. Chem.</u> 267:26031-26037 (1992)8 American Society for Biochemistry and Molecular Biology, Inc.				

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	18	of	30	Prior Application Number	10/076,140
				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RJ	B231	HOWARD, Harry R., "Lactam Derivatives," U.S. Provisional Patent Application Number 60/015134 (3/29/96)			
RJ	B232	HOWARD et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone-and oxindole-1-acetic acids," <u>Eur. J. Med. Chem.</u> 27:779-789 (1992) 8 Elsevier, Paris			
RJ	B233	HU et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," <u>Molecular and Cellular Biology</u> 12:981-990 (1992) copyright Am. Soc. Microbiol.			
RJ	B234	IJAZ et al., "The Conversion of o,β-Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," <u>J. Chem. Res. (S)</u> : 116 (1990)			
RJ	B235	JELLINEK et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994) 8 American Chemical Society			
RJ	B236	KASHISHIAN and COOPER, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cy1," <u>Molecular Biology of the Cell</u> 4:49-57 (1993) 8 The American Society for Cell Biology			
A	B237	KASHISHIAN et al., "Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase <i>in vivo</i> ," <u>The EMBO Journal</u> 11:1373-1382 (1992)			
RJ	B238	KATO et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> 616:67-71 (1993) 8 Elsevier Science			
RJ	B239	KATRITZKY et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," <u>J. Heterocyclic Chem.</u> 25:1287-1292 (1988)			

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted: <i>(use as many sheets as necessary)</i>				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	19	of	30	Attorney Docket Number	034536-0188

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
<i>RK</i>	B240	KAZLAUSKAS et al., "The 64-kDa protein that associates with the platelet-derived growth factor receptor $\beta$ subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993)	
<i>RK</i>	B241	KENDALL and THOMAS, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)	
<i>RK</i>	B242	KHALIL and ABDEL-RAHMAN, "Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes," <u>J. Indian Chem. Soc.</u> 54:904-907 (1977) 8The Indian Chemical Society	
<i>RK</i>	B243	KIKUMOTO et al., "The Reactions of Oxindoles and Isatin with Nitrobenzyl Chlorides," <u>Tetrahedron</u> 22: 3337-3343 (1966) 8Pergamon Press Ltd.	
<i>RK</i>	B244	KIM et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)	
<i>RK</i>	B245	KINSELLA et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:56-62 (1992) 8 Academic Press, Inc.	
<i>RK</i>	B246	KLAGSBURN and SOKER, "VEGF/VPF: the angiogenesis factor found?" <u>Current Biology</u> 3:699-702 (1993) 8Current Biology	
<i>RK</i>	B247	KOBAYASHI et al., "Anti-tumor Activity of Indole Derivatives," <u>Yakugaku Zasshi</u> 97:1033-1039 (1977)	
<i>RK</i>	B248	KOCH et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991)	

Examiner Signature	<i>Robert Koch</i>	Date Considered	<i>12/2/05</i>
--------------------	--------------------	-----------------	----------------

<sup>2</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted: (use as many sheets as necessary)				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	20	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RK	B249	KOHLER and MILSTEIN, "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> 256:495-497 (1975)			
MJ	B250	KOMADA and KITAMURA, "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," <u>Oncogene</u> 8:2381-2390 (1993)			
RF	B251	KORC et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer Is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992) copyright The American Society for Clinical Investigation, Inc.			
RF	B252	KORZENIEWSKI and CALLEWAERT, "An Enzyme-Release Assay for Natural Cytotoxicity," <u>J. Immunol. Methods</u> 64:313-320 (1983) 8 Elsevier Science Publishers			
RF	B253	KOVAC and STETNOVA, "Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoindoles," <u>Chem. ryesu</u> 30:484-492 (1976)			
RF	B254	KRUEGER and SAITO, "A human transmembrane protein-tyrosine-phosphatase, PTPb, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases," <u>Proc. Natl. Acad. Sci. USA</u> 89:7417-7421 (1992)			
RF	B255	KUMABE et al., "Amplification of $\alpha$ -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)			
RF	B256	LAL et al., "Novel Diuretic Agents: Syntheses of Substituted Isatylidene & 3-Alky or 3-Arylalkyl-2-oxindoles," <u>Indian Journal of Chemistry</u> 13: 898-903 (1975)			
RF	B257	LAROCK and BABU, "Synthesis of Nitrogen Heterocycles via Palladium-catalyzed Intramolecular Cyclization," <u>Tetrahedron Letters</u> 28:5291-5294 (1987) copyright Pergamon Journals Ltd.			

Examiner Signature		Date Considered	12/2/03
--------------------	--	-----------------	---------

<sup>1</sup>EXAMINER: Initial if reference considered. Whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)				<b>Complete If Known</b>	
Sheet	21	of	30	Prior Application Number	10/076,140
				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RJ	B258	LEE and DONOGHUE, "Intracellular Retention of Membrane-Anchored v-sis Protein Abrogates Autocrine Signal T transduction," <u>J. Cell. Biol.</u> 118:1057-1070 (1992) 8The Rockefeller University Press			
RJ	B259	LEVITZKI and GAZIT, "Tyrosine Kinase Inhibition: An Approach to Drug Development," <u>Science</u> 267:1782-1788 (1995)			
RJ	B260	MAASS et al., "Viral Resistance to the Thiazolo-Iso-Indolinones, a New Class of Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <u>Antimicrobial Agents and Chemotherapy</u> 37:2612-2617 (1993) 8American Society for Microbiology			
RJ	B261	MACAULAY et al., "Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells," <u>Cancer Research</u> 50:2511-2517 (1990)			
RJ	B262	MARIANI et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (March 1994)			
RJ	B263	MARTIN-LEON et al., "On the Cyclization to the Elusive Amino-4H-pyran Ring Some New Facts," <u>Liebigs Ann. Chem.</u> 101-104 (1990) copyright VCH Verlags of Sellschaft mbH 8VCH			
RJ	B264	MEL'NIKOVA TV et al., "Indole chemistry. XXXVIII. Cleavage of a carbon-carbon bond during the reaction of 2-aminoindoles with difunctional compounds," <u>Chemical Abstracts</u> 80 (1974) Abstract No. 003413			
RJ	B265	MILLAUER et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993) 8 Cell Press			
RJ	B266	MOHAMMADI et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors," <u>Science</u> 276:955-960 (1997) 8 American Association for the Advancement of Science			

Examiner Signature		Date Considered	12/10/05
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted:				Prior Appl. Filing Date	February 15, 2002
(use as many sheets as necessary)				First Named Inventor	Huiping GUAN et al.
Sheet	22	of	30	Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RJ	B267	MORETO et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (DAN-603) in the Rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976) North-Holland Publishing Company			T <sup>6</sup>
RJ	B268	MORETO et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," <u>Arzneimittel-Forschung Drug Research</u> 29:1561-1564 (1979)			
RJ	B269	MORRISON et al., "Signal Transduction From Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 Phosphorylation and Associated Protein Kinase Activity," <u>Proc. Natl. Acad. Sci. USA</u> 85:8855-8859 (1988)			
A	B270	MOSMANN, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983) copyright Elsevier Publishers B.V.			
RJ	B271	NEBER and RÖCKER, "On the action of benzaldehydes on the free o-aminophenylacetic acid (II)," <u>Chem. Ber.</u> 56:1710-1716 (1923) (GERMAN AND ENGLISH TRANSLATION)			
A	B272	NISHIMURA et al., "Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:6889-6896 (1993)			
A	B273	NODIFF et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," <u>J. Med. Chem.</u> 14:921-925 (1971)			
RJ	B274	NODIFF et al., "Antimalarial Phenanthrene Amino Alcohols. 3. Halogen-containing 9-phenanthrenemethanols," <u>Chemical Abstracts</u> , Vol. 83, abstract no. 188214 (1975)			
RJ	B275	OSBORNE et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985)			

Examiner Signature		Date Considered	12/12/05
--------------------	---	-----------------	----------

<sup>2</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted:				Prior Appl. Filing Date	February 15, 2002
(use as many sheets as necessary)				First Named Inventor	Huiping GUAN et al.
Sheet	23	of	30	Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>RL</i>	B276	O'SULLIVAN and ROTHERY, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenides," <u>Clinica Chimica Acta</u> 62:181-182 (1975) Elsevier Scientific Publishing Company			
<i>RL</i>	B277	OZZELLO and SORDAT, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980)			
<i>RL</i>	B278	PAVLENKO et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," <u>Dopov. Akad. Nauk Ukr Rsr, Ser. B: Geol., Khim. Biol. Nauki</u> 7:64-66 (1980) We should add that we are Sub. Abstract			
<i>RL</i>	B279	PERKIN et al., "Harmine and Harmaline. Part II. The Synthesis of isoHarman," <u>J. Chem. Soc.</u> 103:1973-1985 (1913)			
<i>RL</i>	B280	PLATE et al., "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas <u>in vivo</u> ," <u>Nature</u> 359:845-848 (1992)			
<i>RL</i>	B281	PLOWMAN et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&amp;P</u> 7:334-339 (1994)			
<i>RL</i>	B282	QUALICH et al., "A General Oxindole Synthesis," <u>J. Synthetic Organic Chemistry</u> : 51-51 (1993)			
<i>RL</i>	B283	QUINN et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993)			
<i>RL</i>	B284	ROZAKIS-ADCOCK et al., "Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," <u>Nature</u> 360:689-692 (1992)			

Examiner Signature	<i>Rebecca Ander</i>	Date Considered	12/2/05
--------------------	----------------------	-----------------	---------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted: (use as many sheets as necessary)				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	24	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>RJ</i>	B285	RUVEDA and GONZALEZ, "Geometric isomerism in benzylideneoxindoles," <u>Spectrochimica Acta</u> 26A:1275-1277 (1970)			
<i>RJ</i>	B286	RYGAARD and POVLSEN, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta Path. Microbiol. Scand.</u> 77:758-760 (1969)			
<del>RJ</del>	B287	<del>SAINSBURY et al., "Electrochemical Oxidation of Aromatic Ethers. Part 5.<sup>1</sup> Further Studies of the Coupling Reactions of Alkoxyinated Aralkyl- and Aryl-amides," J.C.S. Perkin I 108-114</del>			
<i>RJ</i>	B288	SAITO and STREULI, "Molecular Characterization of Protein Tyrosine Phosphatases," <u>Cell Growth &amp; Differentiation</u> 2:59-65 (1991) 8 Molecular Biology Journal of the American Association for Cancer Research			
<i>RJ</i>	B289	SANDBERG-NORDQVIST et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," <u>Cancer Research</u> 53:2475-2478 (1993)			
<i>RJ</i>	B290	SCHINDLER et al., "Über Dibenz[b,f]-azocin-Derivate," <u>Helvetica Chimica Acta</u> 49:985-989 (1966)			
<i>RJ</i>	B291	SCHLESSINGER and ULLRICH, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992) 8 Cell Press			
<i>RJ</i>	B292	SCHUCHTER et al., "Successful Treatment of Murine Melanoma with Bryostatin 1," <u>Cancer Research</u> 51:682-687 (1991)			
<i>RJ</i>	B293	SEIBERT et al., "Clonal Variation of MCF-7 Breast Cancer Cells <u>in Vitro</u> and in Athymic Nude Mice," <u>Cancer Research</u> 43:2223-2234 (1983)			

Examiner Signature	<i>Leben Lander</i>	Date Considered	<i>12/1/05</i>
--------------------	---------------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

\* no date provided *RJ*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted: (use as many sheets as necessary)				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	25	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RG	B294	SHAFIE and GRANTHAM, "Role of Hormones in the Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted Into Athymic Nude Mice," <u>J. Natl. Cancer Institute</u> 67:51-56 (1981)			
RG	B295	SHIBUYA et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family," <u>Oncogene</u> 5:519-524 (1990)			
RG	B296	SHIRAISHI et al., "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147:322-328 (1987) Academic Press			
RG	B297	SHIRAISHI et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamamide Derivatives <i>in Vitro</i> ," <u>Cancer Research</u> 49:2374-2378 (1989)			
RG	B298	SHWEIKI et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," <u>Nature</u> 359:843-845 (1992)			
RG	B299	SINGH et al., "Indolinone Derivatives as Potential Antimicrobial Agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989) copyright VEB Gustav Fischer Verlag Jena			
RG	B300	SINGH et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxospiro (Azetidin-3', 4-Indol-2' Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994)			
RG	B301	SKEHAN et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl. Cancer Inst.</u> 82:1107-1112 (1990)			
RG	B302	SLAMON et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)			

Examiner Signature		Date Considered	12/2/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	26	of	30	Prior Application Number	10/076,140
				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
<i>RL</i>	B303	SOLDI et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125 <sup>FAK</sup> ) in Human Endothelial Cells," <u>Oncogene</u> 13:515-525 (1996) copyright Stockton Press		
<i>RL</i>	B304	SONGYANG et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993) 8 Cell Press		
<i>RL</i>	B305	SONGYANG et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994) 8 American Society for Microbiology		
<i>RL</i>	B306	SPADA, et al., "Small molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5:805-817 (1995) 8Ashley Publications		
<i>RL</i>	B307	STETINOVA et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," <u>Collection Czechoslov. Chem. Commun.</u> 42:2201-2206 (1977)		
<i>RL</i>	B308	STOLLE, <u>Beilstein Reg. No. 273650, J. Prakt. Chem.</u> , Vol. 2, page 128 (1930)		
<i>RL</i>	B309	STOLLE, <u>Beilstein Reg. No. 305045, J. Prakt. Chem.</u> , Vol. 2, page 128 (1930)		
<i>RL</i>	B310	SUMPTER and MILLER, "Chapter IV – Oxindole," in <u>Heterocyclic Compounds With Indole and Carbazole Systems</u> , 8 Interscience Publishers, Inc., New York, pp. 134-153 (1954)		
<i>XJ</i>	B311	SUN et al., "Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylideny]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," <u>Journal of Medicinal Chemistry</u> 42: 5120-5130 (1999) 8American Chemical Society		

Examiner Signature	<i>Lebra Anderson</i>	Date Considered	<i>12/12/05</i>
--------------------	-----------------------	-----------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)				<b>Complete If Known</b>	
Sheet	27	of	30	Prior Application Number	10/076,140
				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0188

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RJ	B312	SUN et al., "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," <u>J. Med. Chem.</u> 41:2588-2603 (1998) 8The American Chemical Society			T <sup>6</sup>
RJ	B313	SUPERTI-FURGA et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech.</u> 14:600-605 (1996)			
RJ	B314	SUPERTI-FURGA et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993) 8 Oxford University Press			
RJ	B315	TACCONI and MARINONE, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," <u>Ricerca Scientifica</u> 38:1239-1244 (1968)			
RJ	B316	TACCONI et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," <u>J.C.S. Perkin II</u> 150-154 (1976)			
RJ	B317	TAKANO et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits Protein Kinase C," <u>Mol. Bio. Cell</u> 4:358A at abstract no. 2076 (1993)			
RJ	B318	TERRETT et al., "Combinatorial Synthesis - The Design of Compound Libraries and their Application to Drug Discovery," <u>Tetrahedron</u> 51(30):8135-8173 (1995) copyright Pergamon! all even pages missing!			
RJ	B319	THIO et al., "The Interconversion of 2-(2-Aminophenyl)-3-piperolidinone and 3-(2-piperidylmethyl)-2-indolinone: A Reversible N = N' Transacylation," <u>Notes</u> (1971) 479-482			
RJ	B320	THOMPSON et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," <u>J. Chem. Soc. Perkin Trans. (I)</u> 1835-1837 (1993)			

Examiner Signature	<i>Karen J. Sleser</i>	Date Considered	12/12/05
--------------------	------------------------	-----------------	----------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
Date Submitted: (use as many sheets as necessary)				Prior Application Number	10/076,140
				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	28	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
RL	B321	TORP et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," <u>APMIS</u> 100:713-719 (1992)				
RL	B322	TRAXLER, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997) 8 Ashley Publications Ltd.				
RL	B323	TSAI et al., "The Effect of 3,3-Di-Pyridyl Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31:943-947 (1992) 8 Pergamon Press				
RL	B324	TUZI et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)				
RL	B325	TWAMLEY-STEIN et al., "The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells," <u>Proc. Natl. Acad. Sci. USA</u> 90:7696-7700 (1993)				
RL	B326	ULLRICH and SCHLESSINGER, "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> 61:203-212 (1990) copyright Cell Press				
RL	B327	VAISMAN et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990) 8 The American Society for Biochemistry and Molecular Biology				
RL	B328	VARMA and GUPTA, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quiazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989) 8 The Indian Chemical Society				
RL	B329	VOLLER et al., "Ch. 45 – Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 <sup>nd</sup> edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980); @ American Society for Microbiology				

Examiner Signature		Date Considered	12/2/08
--------------------	---	-----------------	---------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	10/076,140
Date Submitted: <i>(use as many sheets as necessary)</i>				Prior Appl. Filing Date	February 15, 2002
				First Named Inventor	Huiping GUAN et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	29	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>RL</i>	B330	WAHL et al., "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," <u>Ann. Chim.</u> 350 (1926), DATABASE CROSSFIRE, Beilstein Reference No. 2-21-00-00290			
<i>RL</i>	B331	WAHL et al., "Chimie Organique - Sur les Iso-indogenides," <u>C.R. Hebd. Seances Acad. Sci.</u> 149:132-134 (1909)			
<i>RL</i>	B332	WAHL, Beilstein Reg. No. 191439, <u>Bull. Soc. Chim. Fr.</u> , page 1038 (1909)			
<i>RL</i>	B333	WAHL, Beilstein Reg. No. 231732, <u>Bull. Soc. Chim. Fr.</u> , pages 1035-1038 (1909)			
<i>RL</i>	B334	WALKER, "Synthesis of a $\alpha$ -(p-Aminophenyl)- and $\alpha$ -(p-Chlorophényl)- $\beta$ -aryl-propionitriles by Catalytic Reduction of Stilbenenitriles," <u>J. Med. Chem.</u> 8:583-588 (1965)			
<i>RL</i>	B335	WALKER et al., "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-( $\beta$ -Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8:626-637 (1965)			
<i>RL</i>	B336	WARRI et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-I Human Breast Cancer Cells <u>In Vitro</u> and in Nude Mice," <u>Int. J. Cancer</u> 49:616-623 (1991) 8 Wiley-Leiss, Inc.			
<i>RL</i>	B337	WEIDNER et al., "Tumor Angiogenesis and Metastasis -- Correlation in Invasive Breast Carcinoma," <u>New England J. Medicine</u> 324:1-7 (1991) 8 Massachusetts Medical Society			
<i>RL</i>	B338	WINCKELMANN et al., "Chemotherapeutically Active Nitro Compounds: 4, 5-Nitroimidazoles (Part I)," <u>Arzneim.-Forsch./Drug Res.</u> 27:2251-2263 (1977)			

Examiner Signature	<i>Kehua Anden</i>	Date Considered	<i>12/2/03</i>
--------------------	--------------------	-----------------	----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>					
Date Submitted: <i>(use as many sheets as necessary)</i>					
Sheet	30	of	30	Attorney Docket Number	034536-0188

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
<i>ZL</i>	B339	WRIGHT et al., "Cyclic Hydroxamic Acids Derived from Indole," <u>J. Am. Chem. Soc.</u> 78:221-224 (1956)			
<i>ZL</i>	B340	WRIGHT et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)			
<i>ZL</i>	B341	YOUNG and BABBITT, "2-(2-Methyl-3-indolyl)-1,4-benzoquinone, a Reversible Redox Substrate at the Carbon-Paste Electrode in Acidic Aqueous-Ethanolic Media," <u>J. Org. Chem.</u> 47:1571-1572 (1982) copyright Am. Chem. Soc.			
<i>ZL</i>	B342	ZAMAN et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β-Receptor (β-PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57:57-64 (1999) Elsevier Science Inc.			
<i>ZL</i>	B343	ZHANG et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:228-234 (1996) The American Society for Pharmacology and Experimental Pharmacetics			
<i>ZL</i>	B344	ZHUNGIETU et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," <u>Chemical Abstracts</u> , Vol. 78, abstract no. 111201 (1990)			

Examiner Signature	<i>Karen J. Sander</i>	Date Considered	<i>12/12/05</i>
--------------------	------------------------	-----------------	-----------------

<sup>2</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.